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Background: CD13 is selectively upregulated in angiogenic active endothelium and can serve as a target for
molecular imaging tracers to non-invasively visualise angiogenesis in vivo. Non-invasive determination of CD13
expression can potentially be used to monitor treatment response to pro-angiogenic drugs in ischemic heart
disease. CD13 binds peptides and proteins through binding to tripeptide asparagine-glycine-arginine (NGR) amino
acid residues.
Previous studies using in vivo fluorescence microscopy and magnetic resonance imaging indicated that cNGR
tripeptide-based tracers specifically bind to CD13 in angiogenic vasculature at the border zone of the infarcted
myocardium.
In this study, the CD13-binding characteristics of an 111In-labelled cyclic NGR peptide (cNGR) were determined.
To increase sensitivity, we visualised 111In-DTPA-cNGR in combination with 99mTc-sestamibi using dual-isotope
SPECT to localise CD13 expression in perfusion-deficient regions.
Methods: Myocardial infarction (MI) was induced in Swiss mice by ligation of the left anterior descending coronary
artery (LAD). 111In-DTPA-cNGR and 99mTc-sestamibi dual-isotope SPECT imaging was performed 7 days post-ligation
in MI mice and in control mice. In addition, ex vivo SPECT imaging on excised hearts was performed, and
biodistribution of 111In-DTPA-cNGR was determined using gamma counting. Binding specificity of 111In-DTPA-cNGR
to angiogenic active endothelium was determined using the Matrigel model.
Results: Labelling yield of 111In-DTPA-cNGR was 95% to 98% and did not require further purification. In vivo,
111In-DTPA-cNGR imaging showed a rapid clearance from non-infarcted tissue and a urinary excretion of 82% of the
injected dose (I.D.) 2 h after intravenous injection in the MI mice. Specific binding of 111In-DTPA-cNGR was
confirmed in the Matrigel model and, moreover, binding was demonstrated in the infarcted myocardium and
infarct border zone.
Conclusions: Our newly designed and developed angiogenesis imaging probe 111In-DTPA-cNGR allows
simultaneous imaging of CD13 expression and perfusion in the infarcted myocardium and the infarct border zone
by dual-isotope micro-SPECT imaging.
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The formation of new capillaries from existing micro ves-
sels occurs as a natural healing process following myocar-
dial infarction (MI) [1]. This process, called angiogenesis,
is triggered by ischemia and results in partial restoration
of blood perfusion in the ischemic zone. Importantly, the
extent of angiogenesis is associated with post-infarct re-
modelling and has positive implications for the prognosis
of MI patients [2]. Several therapy approaches, aimed
at stimulating angiogenesis in the infarcted area, in-
cluding gene therapy, intramyocardial administration of
pro-angiogenic factors, administration of bone marrow-
derived stem cells, and transmyocardial revasculariza-
tion have been tested [3-12]. To date, results in animal
models have been encouraging [3-5]. Nonetheless, the
clinical translation of these therapies has proven to be
difficult, and the clinical benefit for MI patients has
been disappointing and controversial [6-12].
In order to improve treatment options, assessing the
efficacy of pro-angiogenic therapies and monitoring the
temporal development of angiogenesis, non-invasive me-
thods (e.g. molecular imaging) are warranted. A sensitive
and specific molecular imaging marker for angiogenesis,
however, is still missing.
Angiogenic vessels demonstrate upregulation of CD13,
a membrane-bound aminopeptidase, on activated endo-
thelial cells [13,14]. The cyclic tripeptide Asn-Gly-Arg
(cNGR) homes to CD13 expressed on endothelial cells
of angiogenic tumour vasculature and angiogenic vessels
in the infarcted area and border zones of the myocar-
dium [14-19]. Moreover, evidence was obtained that
cNGR does not bind to CD13-positive macrophages in
the infarcted myocardium and infarct border zone. This
finding was ascribed to cNGR, possibly targeting a sub-
set of post-translationally modified CD13 that might be
specific to smaller and perhaps newly formed vessels
[17]. Furthermore, using polymerase chain reaction,
peak expression of CD13 was shown 7 days after MI in
a mouse myocardial infarction model [15]. Non-invasive
imaging of CD13 in mice has further been demonstrated
with cNGR-labelled paramagnetic quantum dots for
molecular magnetic resonance imaging (MRI) [20]. Al-
though angiogenic activity could selectively and non-
invasively be depicted in the infarcted heart, molecular
imaging with MRI requires high contrast agent dosage,
which hampers translation to clinical trials.
The arginine-glycine-aspartic-acid (RGD) motif is
known to label angiogenic active endothelium through
binding to αvβ3 integrin [21]. In several pre-clinical studies
in different neovascularisation models, RGD conjugated
agents have been employed [2,22]. However, competition
studies in tumour angiogenesis with the NGR and RGD
motif demonstrated a threefold higher target homing ratio
(tumour/control organ) for NGR than that for RGD [16].In this study, we designed and developed a CD13 mo-
lecular imaging probe that allowed sensitive visualisation
using micro-SPECT imaging. In order to target CD13,
we used the cNGR tripeptide, having a tenfold higher
targeting efficacy than the linear entity [23], to design a
non-invasive angiogenesis imaging probe. Thereto, the
cNGR tripeptide was conjugated with diethylene tria-
mine pentaacetic acid (DTPA), radiolabeled with 111In
and evaluated in a mouse model of myocardial infarc-
tion in combination with 99mTc-sestamibi in dual-isotope
micro-SPECT imaging. In order to determine binding spe-
cificity of our newly designed probe, we employed the vali-





(4MeBzl)-Gly-Gly-Lys(2 chloro-Z)-peptide was synthe-
sised by tert-butyloxycarbonyl (tBoc) solid-phase pep-
tide synthesis, on 4-methylbenzhydryl amine resin, as
described before [15,24]. After coupling of the last ami-
no acid, the Boc-protecting group was cleaved and the
peptide was Nα acetylated (10 mL DMF + 230 μL acetic
anhydride + 190 μL pyridine, 2 × 2 min). Resin-bound
peptide (0.35 g) was cleaved and simultaneously depro-
tected in anhydrous HF (1 h, 0°C) with 4 vol.% p-cresol
as a scavenger and the product was precipitated with
ice-cold diethyl ether, collected on a glass filter, eluted
from the filter using H2O/CH3CN/TFA (50:50:0.1 v/v/v)
and lyophilized to give crude material containing NAc-
Cys-Asn-Gly-Arg-Cys-Gly-Gly-Lys-NH2. Subsequently,
31.1 mg crude NAc-Cys-Asn-Gly-Arg-Cys-Gly-Gly-Lys-
NH2 was dissolved in 50 mL 0.1 M TRIS buffer (pH 8),
containing 1 M Gn HCl. The resulting solution was stirred
for 3 h at room temperature to form the internal disulfide
bond. Reaction progress was monitored by analytical
HPLC, and after reaction completion, oxidised NAc-Cys-
Asn-Gly-Arg-Cys-Gly-Gly-Lys-NH2 was purified by semi-
preparative HPLC.
Cys-DTPA was coupled to the C-terminal lysine resi-
due of cNGR peptide through a bifunctional succinimi-
dyl ester-maleimide linker, sulfo-SMCC [25]. Therefore,
6.3 mg (7.6 μmol) cyclic(NAc-Cys-Asn-Gly-Arg-Cys-
Gly-Gly-Lys; cNGR) and 3.5 mg (8.0 μmol; 1.1 eq) sulfo-
SMCC were dissolved in 2 mL 0.2 M phosphate buffer
(pH 7.5) containing 6 M Gn HCl. After 3.5 h, the re-
action mixture was purified by semi-preparative HPLC.
Finally, 4.1 mg (4.1 μmol) SMCC-cNGR and 3.5 mg
(6.2 μmol; 1.5 eq) Cys-DTPA were dissolved in 400 μL
6 M Gn HCl, 0.2 M phosphate buffer (pH 6.5). The result-
ing solution was stirred at 37°C, and reaction progress was
monitored by analytical HPLC. After reaction completion,
the reaction mixture was purified by preparative HPLC,
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overall yield 34.3%).
Animal studies
MI was induced in 10- to 12-week old male Swiss mice
by ligation of the left anterior descending coronary artery
(LAD) (n = 7), as previously described [26]. The angiogen-
esis imaging protocol was performed 7 days after the LAD
ligation. A group of non-operated male Swiss mice (n = 5)
was used as control. A variable number of animals were
available for analysis per experiment. For SPECT scans,
seven MI mice and five control mice were used while for
biodistribution purposes ≥5 MI mice and ≥4 control mice
were used. Furthermore, a group of six 10- to 12-week old
male Swiss mice were bilaterally, subcutaneously implan-
ted in the flanks with Matrigel (Table 1). These Matrigels
were supplemented with either the pro-angionenic human
fibroblast growth factor 2 (hFGF2, final concentration in
Matrigel: 0.15 μg/ml) or phosphate-buffered saline (PBS)
solution as a control to specifically induce the presence of
angiogenic active endothelium. All animals were held
under the guidelines of the animal care facility (Maastricht
University). All animal experiments were approved by the
Committee for Animal Welfare of Maastricht University.
Imaging probes
111In-DTPA-cNGR
Ten micrograms of DTPA-cNGR was dissolved in
0.5 ml of NaAc buffer (0.5 M, pH6) and radiolabeled
with 111InCl3 (400 to 600 MBq, in ± 0.2 ml 0.1 M HCl,
Mallinckrodt, Petten, The Netherlands) at room tempe-
rature for 30 min. Product purity was checked by HPLC
(Shimadzu Corporation, Columbia, MD, USA) using an
Aeris WIDEPORE 3.6u XB-C18 column 250 × 4.6 mm
(Phenomenex, Utrecht, The Netherlands) eluted with a
gradient from 0.1% trifluoroacetic acid (TFA) in water (0
to 3 min) to acetonitrile (ACN) over the course of 20 min
at a flow rate of 1 ml/min.
99mTc-sestamibi
99mTc-sestamibi was prepared with freshly eluted per-
technetate from a 99Mo/99mTc generator (UltraTechneKow,
Mallinckrodt Medical, Petten, The Netherlands). A fractionTable 1 Overview of the number of animals that were subject
Scan Scan protocol








Ex vivo; heart slices of MI mice 1 time frame (240 min)
Ex vivo; explanted Matrigels 1 time frame (180 min) 90
aSix Swiss mice were implanted bilaterally subcutaneously with Matrigels (hFGF2-suof the eluate was added to the lyophilized sestamibi-kit
(Mallinckrodt Medical, Petten, The Netherlands), and the
product was prepared according to manufacturer guide-




Mice were anesthetised with isoflurane (induction 2.5%;
maintenance; 1.5%), a catheter was placed in the tail
vein and the animals were positioned in the micro-
SPECT camera (MiLabs, Utrecht, The Netherlands).
SPECT reconstructions
U-SPECT-II reconstruction software version 2.38 (MiLabs,
Utrecht, The Netherlands) was used to reconstruct images
[27]. 99mTc and 111In images were reconstructed by select-
ing the photopeak (PP) and background (BG) windows as
indicated in Figure 1.
SPECT quantification
To allow quantification of radiotracer uptake in vivo,
conversion factors (CFs) were determined for the 0.6-mm
collimator system in a representative phantom (20 ml) for
99mTc and/or 111In. During the SPECT reconstruction, the
total amount of counts was distributed over the diffe-
rent voxels, resulting in a counts/voxel expression for
the average concentration of counts. Taking into ac-
count the voxel volume (Vv), the CFs are calculated
using equation (a):




SPECT counts per voxel
Vv mlð Þ
ðaÞ
Using this formula, we were able to determine the fol-
lowing CFs: CFTc = 635 MBq and CFIn = 648 MBq.
The PMOD 2.95 cardiac tool PCARD (PMOD Tech-
nologies, Zürich, Switzerland) was used to segment the
heart in the 17-segment model according to the American
Heart Association (AHA) guidelines. For both the 99mTc-
sestamibi and 111In-DTPA-cNGR images, the uptake wased to different SPECT scans
Injected activity (MBq) Number of Swiss mice used
0 MBq 111In-DTPA-cNGR co-injected
100 to 150 MBq 99mTc-sestamibi
7
0 MBq 111In-DTPA-cNGR co-injected
100 to 150 MBq 99mTc-sestamibi
5
- Out of 7 MI mice, 4 were used
for ex vivo scanning purposes
to 110 MBq 111In-DTPA-cNGR 6a
pplemented or PBS); hence, six pairs of Matrigels were scanned.
Figure 1 Energy spectra of 99mTc, 111In and the PP and BG windows used during image reconstruction.
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dardised uptake value (SUVmean) using equation (b).




 Body weight gð Þ
Injected dose MBqð Þ
 
ðbÞ
For body weight, we assumed that 1 g of body weight
equalled 1 ml.
In order to quantify the absolute uptake of 111In-
DTPA-cNGR in the different heart pieces, gamma coun-
ting was performed using an automated NaI(Tl) gamma
counter (Wallac Wizard, Turku, Finland). Additionally,
we dissected the vital organs of the mice to study overall
biodistribution. The uptake of 111In-DTPA-cNGR was
determined 2 h post-injection (p.i.) for both MI (n ≥ 5)
and control animals (n ≥ 4). Data were expressed as per-
centage of injected dose per gram tissue (%ID/g). Urinal
excretion was expressed as %ID.
Following ex vivo SPECT scans, the explanted Matrigels
were kept for gamma counting. Muscular tissue from the
hind limb was harvested as a reference. The activity per
Matrigel was corrected for ID and weight of the matrigel.
Statistics
Data were expressed as averages for each group ± stand-
ard error of the mean (SEM). To test the significance,
we performed unpaired one-tailed student's t-test and
p < 0.05 was considered statistically significant. Data were
analysed using Microsoft Excel (version 2010).
Results
Chemistry
After cleavage from the solid support with HF, the linear
NGR peptide was cyclised by the formation of an internal
disulfide bond. This resulted in a mass reduction of 2 by
the loss of two protons. MALDI-ToF analysis of the linear
peptide showed a mass of 835.47 (calculated: 834.97;C30H54N14O10S2 [M+H]
+). For the oxidised peptide, a
mass of 833.30 was observed on ESI-MS (calculated:
832.95; C30H52N14O10S2 [M+H]
+) Subsequently, a linker
that contains both an NHS ester and a maleimide reactive
group was coupled to the Nε-group of lysine. Finally, the
maleimide group was used to couple Cys-DTPA. cNGR-
SMCC-DTPA was obtained in an overall yield of 34.3%.
ESI-MS of cNGR-SMCC-DTPA: m/z C63H102N20O24S3
[M +H]+ calculated monoisotopic mass: 1618.65; found:
1619.72.Synthesis of 111In-DTPA-cNGR
The labelling yield of 111In-DTPA-cNGR was 95% to
99% for every synthesis and did not require further
purification.Micro-SPECT imaging and analysis
Transversal tomographic images of the mouse hearts
with MI showed decreased uptake of 99mTc-sestamibi
in the anterolateral region of the left ventricle 7 days
after LAD occlusion (Figure 2), indicating a perfusion
defect. The uptake of 111In-DTPA-cNGR mirrored that
of 99mTc-sestamibi in that the probe was taken up in
areas of low perfusion. These uptake patterns were re-
vealed on images of the in vivo scans and even more
pronounced on images of the ex vivo scans (Figure 2).
In non-infarcted hearts, the uptake of 99mTc-sestamibi
was equally distributed over the whole myocardium
while uptake of 111In-DTPA-cNGR was limited (data
not shown).
Standardised uptake values (SUVs) of 99mTc-sestamibi
were significantly decreased in the anterolateral region
of the left ventricle in infarcted hearts compared to
those in the healthy control mice (Table 2 and Figure 3a).
In the MI mice, six segments displayed significantly
higher 111In-DTPA-cNGR uptake compared to that in
the healthy control hearts (Table 1 and Figure 3b), of which
three had significantly lower 99mTc-sestamibi uptake.
The six segments that displayed significantly enhanced
Figure 2 In vivo and ex vivo transversal tomographic images of an infarcted mouse-heart. (a) In vivo images of 111In-DTPA-cNGR uptake,
mainly in areas of 99mTc-sestamibi absence. Numerical values on the scale bars indicate the SUVmax and SUVmin. (b) Ex vivo images of
111In-DTPA-
cNGR uptake, mainly in areas of 99mTc-sestamibi absence. (c) Polar perfusion maps combined with the 17 segment model show that enhanced
111In-DTPA-cNGR uptake (orange in areas 13, 16 and 17) occurred mainly in areas with low 99mTc-sestamibi uptake (green in areas 13, 16 and 17),
signifying the anterolateral region in the infarcted myocardium.
Hendrikx et al. EJNMMI Research  (2015) 5:2 Page 5 of 10111In-DTPA-cNGR uptake were all located in the in-
farcted myocardium or in the infarct border zone.Biodistribution of 111In-DTPA-cNGR
Considerable kidney uptake of 111In-DTPA-cNGR was
observed, which was significantly higher in the healthy
control mice than that in the MI mice (Figure 4, 4.04 ±
0.41 vs. 2.73 ± 0.42, p = 0.04). The urine (measured as%
ID) contained the highest radioactivity. The difference
between the healthy control and the MI mice was not
significant (92.5 ± 1.17 vs. 82.29 ± 4.87, p = 0.08). A spe-
cific uptake in other organs was limited and did not re-
veal any significant differences between the MI mice and
the healthy control mice (Figure 4).
The uptake of 111In-DTPA-cNGR was significantly
higher in the apical region of the infarcted hearts than in
non-infarcted hearts (%ID/g of 0.16 ± 0.0542 vs. 0.02 ±
0.0050, p = 0.03). The left ventricular and atrial regions
were not significantly different between groups (Figure 5,
p = 0.09 and p = 0.07, respectively). Moreover, uptake of
111In-DTPA-cNGR in healthy myocardium of the left
ventricle was not significantly different between the MI
mice and the healthy control mice (Figure 5).Binding of 111In-DTPA-cNGR to angiogenic active
endothelium
To visualise specific binding of 111In-DTPA-cNGR to
angiogenic active endothelium, we bilaterally implanted
Matrigel plugs in the flanks of six Swiss mice. On the
in vivo SPECT images, the hFGF2 supplemented Matri-
gels were unidentifiable as the kidneys, displaying high up-
take, were in too close proximity. Therefore, we explanted
each Matrigel and performed ex vivo scans. The mean
SUV of explanted hFGF2-supplemented Matrigels was
higher compared with that in the controls (8.238 × 10−4 ±
5.823 × 10−4 vs. 2.2235 × 10−4 ± 7.001 × 10−5, p = 0.1527
and ratio 3.7 supplemented vs. non-supplemented) (see
Additional file 1: Figure S1). Moreover, gamma counter
data of explanted Matrigels indicated a higher uptake
of 111In-DTPA-cNGR between hFGF2-supplemented
and control Matrigels (p = 0.0748). Compared with har-
vested control muscle tissue, a significantly higher up-
take of 111In-DTPA-cNGR was noticed (p = 0.0497) in
hFGF2-supplemented Matrigels (Figure 6).
Discussion
Angiogenesis is associated with post-infarct remodelling
and has important implications for prognosis following
Table 2 Overview of the SUVs of 99mTc-sestamibi and 111In-DTPA-cNGR in healthy control mice (n = 5) and MI mice (n = 7)
Standardised uptake values (SUV)
99mTc-sestamibi 111In-DTPA-cNGR
Segments Healthy control Myocardial infarction Healthy control Myocardial infarction
1. Basal anterior 1.87 ± 0.34 1.94 ± 0.36 0.16 ± 0.05 0.24 ± 0.04
2. Basal anteroseptal 1.63 ± 0.28 1.72 ± 0.33 0.16 ± 0.05 0.21 ± 0.03
3. Basal inferoseptal 1.54 ± 0.29 1.38 ± 0.28 0.13 ± 0.06 0.20 ± 0.02
4. Basal inferior 1.77 ± 0.28 1.64 ± 0.24 0.15 ± 0.05 0.23 ± 0.03
5. Basal inferolateral 1.68 ± 0.30 1.78 ± 0.31 0.14 ± 0.04 0.23 ± 0.03*
6. Basal anterolateral 1.95 ± 0.33 2.11 ± 0.39 0.18 ± 0.06 0.26 ± 0.04
7. Mid anterior 1.80 ± 0.30 1.18 ± 0.26 0.15 ± 0.05 0.21 ± 0.02
8. Mid anteroseptal 1.67 ± 0.28 1.73 ± 0.27 0.14 ± 0.06 0.20 ± 0.02
9. Mid inferoseptal 1.80 ± 0.34 1.82 ± 0.30 0.12 ± 0.06 0.18 ± 0.03
10. Mid inferior 1.72 ± 0.28 1.85 ± 0.31 0.12 ± 0.05 0.17 ± 0.03
11. Mid inferolateral 1.71 ± 0.25 1.60 ± 0.32 0.11 ± 0.04 0.20 ± 0.03
12. Mid anterolateral 2.03 ± 0.32 1.15 ± 0.37 0.15 ± 0.05 0.24 ± 0.01*
13. Apical anterior 1.64 ± 0.30 0.49 ± 0.10* 0.11 ± 0.03 0.21 ± 0.02*
14. Apical septal 1.82 ± 0.34 1.55 ± 0.25 0.12 ± 0.04 0.20 ± 0.03
15. Apical inferior 1.67 ± 0.28 1.36 ± 0.35 0.10 ± 0.03 0.18 ± 0.03*
16. Apical lateral 1.60 ± 0.30 0.64 ± 0.24* 0.14 ± 0.04 0.22 ± 0.02*
17. Apex 1.47 ± 0.34 0.39 ± 0.17* 0.10 ± 0.03 0.20 ± 0.03*
Data are displayed as mean ± S.E.M. *p < 0.05, statistical significance.
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developing pro-angiogenic therapies to stimulate angio-
genesis in the infarcted myocardium [28,29], a clinically
applicable method for the evaluation of these therapies
is still lacking. Most clinical studies thus far have relied
on indirect evidence of myocardial angiogenesis. For
example, changes in stress-induced ischemia and myo-
cardial perfusion were assessed by treadmill exercise
testing and dual-isotope gated SPECT thallium-201/
99mTc-sestamibi perfusion SPECT imaging at baseline,
day 29, day 57 and day 180 after administration of the
pro-angiogenic recombinant-fibroblast growth factor 2
(rFGF2) in a clinical study [9]. In another study, using a
single intracoronary infusion of rFGF2, patients expe-
rienced increased quality of life (assessed by Seattle
Angina Questionnaire) and exercise tolerance (assessed
by treadmill exercise testing). Moreover, in this study,
MRI demonstrated increased regional wall thickening
and a reduction in the extent of the ischemic area com-
pared to baseline [30].
A clinical trial was performed in which patients with
exertional angina were treated with the pro-angiogenic
recombinant human vascular endothelial growth factor
(rhVEGF) [31]. In this trial, no improvement in exercise
treadmill test time or myocardial perfusion, as assessed
by rest-stress thallium-201/99mTc-sestamibi (gated) SPECT
scanning protocol, was detected. However, patients experi-
enced a significant improvement in angina class at day 120after the first administration of rhVEGF [31]. Furthermore,
in a small phase 1 clinical study using VEGF gene transfer,
all patients had significant reduction in angina and ob-
jective evidence of reduced ischemia was documented
using dobutamine 99mTc-sestamibi SPECT imaging. Post-
operative left ventricular ejection fraction (LVEF) was
either unchanged or improved. Moreover, the Rentrop
scoring system, indicating the coronary collateral filling
as assessed by coronary angiography, improved in all
patients [32].
The pro-angiogenic effect of transmyocardial laser
revascularisation (TMLR) was assessed in a small clinical
study (seven patients) by Rimoldi et al. While angina
scores (Canadian Cardiovascular Society) decreased sig-
nificantly, exercise tolerance (treadmill testing), 12-min
walk distance and the LVEF (assessed by radionuclide
ventriculography) remained unchanged. Moreover, des-
pite subjective improvement in some patients, myocar-
dial blood flow (as assessed by 15O-labelled water) during
dobutamine in lasered segments failed to show any signifi-
cant increase [33].
Clearly, improved myocardial perfusion or function
can be used as indirect evidence for angiogenesis in the
infarcted myocardium. Reduced angina scores, increased
treadmill exercise times and improved myocardial perfu-
sion as measured by angiography, SPECT, PET and MRI
all seem to indicate recovery [34]. However, despite the
ability of these methods to indicate recovery, it often
Figure 3 Overview of cardiac 17 segment models for 99mTc-sestamibi and 111In-DTPA-cNGR SUVs. In healthy control hearts and MI hearts.
(a) Cardiac 17 segment models of the healthy control mice and the MI mice indicating colour-coded average 99mTc-sestamibi SUVs per segment.
(b) Cardiac 17 segment models of the healthy control mice and the MI mice indicating colour-coded average 111In-DTPA-cNGR SUVs per
segment. Statistical significance was indicated as asterisk (*) (p < 0.05).
Figure 4 Comparison of 111In-DTPA-cNGR uptake in different
organs. Between the MI (n≥ 5) and the healthy control mice
(n ≥ 4). Significantly higher uptake of 111In-DTPA-cNGR was observed
in the kidneys of the healthy control mice compared to that in the
MI mice (p = 0.04). Statistical significance was indicated as asterisk
(*) (p < 0.05).
Figure 5 Uptake of 111In-DTPA-cNGR. Uptake of 111In-DTPA-cNGR
was significantly higher in the apical region of infarcted hearts
compared to that in the healthy control hearts. Uptake of
111In-DTPA-cNGR was not significantly different in other regions
of the myocardium.
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Figure 6 Uptake of 111In-DTPA-cNGR was higher in hFGF2-
supplemented Matrigels compared with controls. The uptake of
111In-DTPA-cNGR in hFGF2-supplemented Matrigels was significantly
higher compared with that in the control muscle tissue while uptake
of 111In-DTPA-cNGR in the control Matrigels was non-significantly
different compared to that in the control muscle tissue. Data are
displayed as mean ± S.E.M. Statistical significance was indicated as
asterisk (*) (p < 0.05).
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detected. Therefore, these methods, used in current MI
patient care, lack the sensitivity to monitor, or predict,
pro-angiogenic treatment. To make direct angiogenesis
imaging available for MI patient care, sensitive and spe-
cific non-invasive direct angiogenesis imaging probes
are required.
To our knowledge, this is the first time CD13 ex-
pression was visualised with a nuclear cNGR probe in a
mouse model of MI using dual-isotope micro-SPECT
imaging. Simultaneous perfusion-imaging enabled us to
visualise the angiogenesis process in the border zone of
the infarct and the infarcted tissue itself. According to
previous studies from our lab, angiogenesis is expected
to occur in the infarct area and border zone of the in-
farct [15,20]. Additionally, in co-localisation experiments
using the fluorescently labelled endothelial cell marker
anti-CD31-PE, the fluorescently labelled angiogenic active
endothelial cell marker anti-CD105-FITC and fluores-
cently labelled cNGR conjugates, evidence for preferential
binding of cNGR conjugates to angiogenic active endothe-
lial cells of capillaries and larger vessels with an inner
diameter up to 15 μm was provided [15,20]. Moreover,despite the abundant presence of CD13-positive macro-
phages, fluorescently labelled cNGR did not bind to anti-
CD13-FITC labelled macrophages [15]. In the current
study, we used the exact same animal model and the same
cNGR moiety, assuring identical experimental conditions.
Extrapolating from these data, we therefore consider bind-
ing of our 111In-DTPA-cNGR imaging probe to be specific
for angiogenic endothelium.
Specific binding of our probe is further emphasised by
enhanced binding of 111In-DTPA-cNGR to angiogenic
active endothelium in a specific model for angiogenesis.
Unfortunately (hFGF2-supplemented) Matrigels, implan-
ted in the flanks for optimal stimulation of angiogenesis,
were unrecognisable on in vivo SPECT scans as high renal
uptake hampered image analysis. Therefore, we explanted
the Matrigels and performed ex vivo SPECT scans that
indicated higher uptake of 111In-DTPA-cNGR in hFGF2-
supplemented Matrigels compared with control Matrigels.
Moreover, the uptake of 111In-DTPA-cNGR in hFGF2-
supplemented Matrigels was higher compared with that in
the control Matrigels as indicated by gamma counting.
hFGF2-supplemented Matrigels displayed significantly
higher uptake than control muscle tissue, indicating active
angiogenesis.
To use this imaging probe in a clinical setting, the
probe should display a high specific target uptake and
fast clearance from non-specific organs. The biodistribu-
tion characteristics of our probe were studied 2 h post-
injection and demonstrated a rapid clearance in the urine
which is a favourable clearance pathway. This is in con-
trast with results for the hydrophilic RGD probe, mainly
studied for tumour angiogenesis imaging, that demon-
strates unfavourable binding to kidneys, spleen, lungs,
liver, and gastrointestinal system thereby hampering the
image quality [35].
We simultaneously imaged and quantified cardiac up-
take of 99mTc and 111In in the AHA 17 segment model.
The isotope uptake per segment was quantified using
isotope specific CFs, assessed in phantom studies. Fur-
thermore, isotope uptake was expressed in the clinically
used SUV parameter, which normalises for injected dose
and body weight. Although normalisation for body
weight might be considered irrelevant for a rapidly ex-
creted tracer that does not reach a uniform distribution
throughout the body, we believe that the body weight
bias in our quantification is limited due to the fact that
all the animals used in this study were of similar age
and body weight.
We found target-specific binding of our new angio-
genesis imaging probe as evidenced by the significantly
enhanced SUVs in six segments in the infarcted myo-
cardium and the infarct border zone. To even further
improve dual-isotope micro-SPECT imaging of perfu-
sion defects and mirroring 111In-DTPA-cNGR uptake
Hendrikx et al. EJNMMI Research  (2015) 5:2 Page 9 of 10in the hearts of the MI mice, we are currently pursuing
strategies to further enhance probe-target interaction
through multivalent binding which may result in higher
image quality. The proof of principle of this approach
has already been demonstrated in studies from Li et al.
and Dijkgraaf et al., in which tumour uptake increased
with increasing RGD valency [35,36].
Despite displaying enhanced, specific uptake in the
infarcted myocardium and infarct border zone, we ob-
served several remarkable and so far inexplicable fea-
tures of our probe. We found the overall uptake to be
higher in every section of the infarcted hearts compared
with that in the healthy control hearts. This may be due
to enhanced post-infarct overall stress in the heart, but
we cannot confirm such a finding at this moment.
Moreover, kidney uptake was significantly higher in the
healthy control mice compared to that in the MI mice.
Although we currently have no direct link between the
infarct and these findings, these discoveries we made
using SPECT scans were overlooked in earlier studies
employing two-photon microscopy and MRI and may
be of considerable importance for future studies em-
ploying the cNGR molecule as a molecular angiogenesis
imaging probe.
In this study, we opted for 111In due to the fact that
pre-clinical SPECT scanners outclass pre-clinical PET
scanner in terms of spatial resolution. Of course, the use
of 111In in a clinical situation may be less favourable due
to its long physical half-life of 2.8 days and resolution
limitations. While pre-clinical SPECT scanners outclass
pre-clinical PET scanners in terms of spatial resolution,
in the clinical setting, this is reversed. Therefore, angio-
genesis imaging via the cNGR tripeptide in MI patients
would benefit from the use of a clinical PET system. Fu-
ture research should therefore focus on the development
of a high-resolution cNGR-based PET imaging probe,
for example by replacing 111In by the PET isotope 68Ga.
Conclusions
In conclusion, in this study, we designed and developed
a molecular angiogenesis imaging probe that allowed us
to sensitively visualise CD13 in the border zone of in-
farcted myocardium and infarcted myocardium itself
using dual-isotope SPECT imaging. Analysis of acquired
SPECT images in the AHA 17 segment model revealed
target-specific uptake of our new angiogenesis imaging
probe in areas of decreased perfusion. Furthermore, we
noticed rapid clearance via the urinary tract and low
uptake in non-specific organs. However, for the cNGR
tripeptide to be considered as a clinical angiogenesis
imaging tool, specific target uptake has to increase.
Therefore, we are currently pursuing a multi-valent
cNGR motif with supposed longer half-life and higher
target affinity.Additional file
Additional file 1: Figure S1. The SUVs of 111In-DTPA-cNGR in ex vivo
scanned Matrigels. The mean SUV of explanted hFGF2-supplemented
Matrigels was higher compared to that of the controls (8.238 × 10−4 ±
5.823 × 10−4 vs. 2.2235 × 10−4 ± 7.001 × 10−5, p = 0.1527 and ratio 3.7
supplemented vs. non-supplemented).
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